ABOUT MACROGENICS

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART^TM bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. Our product candidates and platforms have attracted partnerships with leading pharmaceutical and biotechnology companies around the globe.

Our immuno-oncology product candidates are currently being tested in Phase 1 – 3 human clinical trials across a variety of tumor types. These molecules have been designed to function through modes of action that could potentially be used as monotherapy, added to standard agents such as chemotherapy, or combined with another pipeline molecule to exploit complementary immune mechanisms. We have submitted a Biologics License Application (BLA) seeking approval for our most advanced product candidate.